Bibliography
- Cavero I, Crumb W. Safety Pharmacology Society: 5th Annual Meeting; 27 – 29 September 2005; Mannheim, Germany. Expert Opin Drug Saf 2006;5:181-5
- Cavero I. Safety Pharmacology Society: 6th Annual Meeting; 26 – 28 September 2006; San Diego, USA. Expert Opinion Drug Saf 2007;6:87-92
- Cavero I. Safety Pharmacology Society: 7th Annual Meeting; 20 – 21 September 2007; Edinburgh, UK. Expert Opinion Drug Saf 2008;7:91-100
- Cavero, I. Safety Pharmacology Society: 8th Annual Meeting 22 – 25 September, 2008, Madison, USA. Expert Opinion Drug Saf 2009;8:1-11
- Cavero I. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Expert Opin Drug Saf 2009;8:627-47
- Davidson L, Greblov G. The Pharmaceutical industry in the global economy. Available from: http://www.bus.indiana.edu/davidso/lifesciences/lsresearchpapers/pharmaceutical%20industryaug12.doc
- Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006;7:889-908
- Löfstedt RE. The impact of the Cox-2 inhibitor issue on perceptions of the pharmaceutical industry: content analysis and communication implications. J Health Commun 2007;12:471-91
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
- Löfstedt RE. The swing of the regulatory pendulum in Europe: from the precautionary principle to (regulatory) impact analysis. J Risk Uncert 2004;28:237-60
- Löfstedt RE. Risk communication and management in the twenty-first century. Int Public Manag J 2004;7:335-346
- Lemmer B. Discoveries of rhythms in human biological functions: a historical review. Chronobiol Int 2009 26:1019-68
- Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease-from mice and man. Pharmacol Ther 2006;111:629-51
- Smolensky MH, Lemmer B, Reinberg AE. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Deliv Rev 2007;59:852-82
- Lemmer B. Chronobiology, drug-delivery, and chronotherapeutics. Adv Drug Deliv Rev 2007;59:825-7
- Portaluppi F, Lemmer B. Chronobiology and chronotherapy of ischemic heart disease. Adv Drug Deliv Rev 2007;59:952-65
- ICH Harmonised Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals S7A. 2000. Available from: www.ich.org/LOB/media/MEDIA504.pdf
- Council Directive of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes (86/609/EEC). Available from: http://ec.europa.eu/food/fs/aw/aw_legislation/scientific/86-609-eec_en.pdf
- Questions and answers on revising the directive for the protection of animals used in scientific experiments Available from: http://europa.eu/rapid/pressReleasesAction.do?reference=MEMO/08/677&format=HTML&aged=0&language EN&guiLanguage=en
- Proposal for a Directive of the European Parliament and of the Council on the protection of animals used for scientific purposes. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52008PC0543:EN:NOT
- Swoap SJ, Overton JM, Garber G. Effect of ambient temperature on cardiovascular parameters in rats and mice: a comparative approach. Am J Physiol Regul Integr Comp Physiol 2004;287:R391-96
- Swoap SJ, Li C, Wess J, Vagal tone dominates autonomic control of mouse heart rate at thermoneutrality. Am J Physiol Heart Circ Physiol 2008;294:H1581-8
- Swoap SJ, Gutilla MJ. Cardiovascular changes during daily torpor in the laboratory mouse. Am J Physiol Regul Integr Comp Physiol 2009;297:R769-74
- Culex® automated in vivo sampling system. Available from: www.basinc.com/products/culex/
- DSI PhysioTel® transmitters. Available from: http://www.datasci.com/products/implantable_telemetry/transmitters.asp
- Guideline on the non-clinical investigation of the dependence potential of medicinal products. Available from: www.emea.europa.eu/pdfs/human/swp/ 9422704en.pdf
- Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). Available from: www.ich.org/LOB/media/ MEDIA5544.pdf
- Busto U, Kaplan HL, Zawertailo L, Sellers EM. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 1994;55:451-63
- Zawertailo LA, Busto U, Kaplan HL, Sellers EM. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. J Clin Psychopharmacol 1995;15:117-24, Erratum in: J Clin Psychopharmacol 1995;15:239
- Bussiere JL, Martin P, Horner M, Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 2009;28:230-53
- Gerber HP, Wu X, Yu L, Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007;104:3478-83
- Kümmerer K. The presence of pharmaceuticals in the environment due to human use-present knowledge and future challenges. J Environ Manage 2009;90:2354-66
- In: Kümmerer K, editor, Pharmaceuticals in the environment: sources, fate, effects and risks. Springer, Berlin, Heidelberg; 2008
- In: Kümmerer K, Hempel M, editors, Green and sustainable pharmacy. Springer, Berlin, Heidelberg; 2010
- Available from: www.multicase.com
- Available from: www.leadscope.com
- Derek for Window. Available from: www.lhasalimited.org/documents/brochure_derek.pdf
- Marchant CA, Briggs KA, Long A. In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for windows, meteor, and vitic. Toxicol Mech Methods 2008;18:177-87
- Niculescu-Duvaz I. Glufosfamide (Baxter Oncology). Curr Opin Investig Drugs 2002;3:1527-32
- Kümmerer K. Sustainable from the very beginning: rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry. Green Chem 2007;9:899-907
- Valentin JP, Bialecki R, Ewart L, A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 2009;60:152-8
- ICH Harmonised Tripartite Guideline. Safety evaluation of biotechnology-derived pharmaceuticals. S6. Available from: www.ich.org/LOB/media/MEDIA503.pdf
- ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available from: www.ich.org/LOB/media/MEDIA2192.pdf
- Boelsterli UA. Animal models of human disease in drug safety assessment. J Toxicol Sci 2003;28:109-21
- Herman EH, Ferrans VJ. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 1998;25(4 Suppl 10):15-21
- Herman EH, el-Hage AN, Ferrans VJ, Ardalan B. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol 1985;78:202-14
- Chien KR. Herceptin and the heart–a molecular modifier of cardiac failure. N Engl J Med 2006;354:789-90
- Ichinose M, Barnes PJ. Histamine H3 receptors modulate antigen-induced bronchoconstriction in guinea pigs. J Allergy Clin Immunol 1990;86(4 Pt 1):491-5
- Gintant GA. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 2008;119:199-209
- Fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV. Available from: www.fda.gov/downloads/Drugs/ GuidanceCompliance RegulatoryInformation/ Guidances/UCM079742.pdf
- Guideline on fixed combination medicinal products. Available from: www.emea.europa.eu/pdfs/human/ewp/024095en.pdf
- Kümmerer K, Velo G. A new topic of importance in pharmacovigilance. Drug Saf 2006;29:371-3